201 related articles for article (PubMed ID: 23222459)
21. Distinct Serum and Vitreous Inflammation-Related Factor Profiles in Patients with Proliferative Vitreoretinopathy.
Ni Y; Qin Y; Huang Z; Liu F; Zhang S; Zhang Z
Adv Ther; 2020 May; 37(5):2550-2559. PubMed ID: 32274748
[TBL] [Abstract][Full Text] [Related]
22. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114
[TBL] [Abstract][Full Text] [Related]
23. Vitreous M2 Macrophage-Derived Microparticles Promote RPE Cell Proliferation and Migration in Traumatic Proliferative Vitreoretinopathy.
Song Y; Liao M; Zhao X; Han H; Dong X; Wang X; Du M; Yan H
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):26. PubMed ID: 34554178
[TBL] [Abstract][Full Text] [Related]
24. Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy.
La Heij EC; van de Waarenburg MP; Blaauwgeers HG; Kessels AG; Liem AT; Theunissen C; Steinbusch H; Hendrikse F
Am J Ophthalmol; 2002 Sep; 134(3):367-75. PubMed ID: 12208248
[TBL] [Abstract][Full Text] [Related]
25. Altered Decorin Biology in Proliferative Vitreoretinopathy: A Mechanistic and Cohort Study.
Begum G; O'Neill J; Chaudhary R; Blachford K; Snead DRJ; Berry M; Scott RAH; Logan A; Blanch RJ
Invest Ophthalmol Vis Sci; 2018 Oct; 59(12):4929-4936. PubMed ID: 30347087
[TBL] [Abstract][Full Text] [Related]
26. Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Yamamoto S; Yamamoto T; Tsukahara I; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Jpn J Ophthalmol; 2002; 46(2):218-21. PubMed ID: 12062231
[TBL] [Abstract][Full Text] [Related]
27. Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid.
Asaria RH; Kon CH; Bunce C; Sethi CS; Limb GA; Khaw PT; Aylward GW; Charteris DG
Br J Ophthalmol; 2004 Nov; 88(11):1439-42. PubMed ID: 15489490
[TBL] [Abstract][Full Text] [Related]
28. Placenta growth factor and vascular endothelial growth factor in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Tashimo A; Ohtsuka K; Mizue Y; Nishihira J
Clin Exp Ophthalmol; 2005 Apr; 33(2):226-7. PubMed ID: 15807839
[No Abstract] [Full Text] [Related]
29. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Ohtsuka K; Matsuda A; Yamamoto T; Yamamoto S; Hiraiwa N; Kusakabe M
Ophthalmologica; 2003; 217(6):422-5. PubMed ID: 14573976
[TBL] [Abstract][Full Text] [Related]
30. Elevated adrenomedullin in the vitreous of patients with proliferative vitreoretinopathy.
Udono T; Takahashi K; Takano S; Shibahara S; Tamai M
Am J Ophthalmol; 1999 Dec; 128(6):765-7. PubMed ID: 10612519
[TBL] [Abstract][Full Text] [Related]
31. Defining the seriousness of proliferative vitreoretinopathy by aspiration of cytokines from the anterior chamber.
Rusnak S; Vrzalova J; Hecová L; Kozova M; Topolcan O; Ricarova R
Biomark Med; 2013 Oct; 7(5):759-67. PubMed ID: 24044568
[TBL] [Abstract][Full Text] [Related]
32. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
33. Vitreous levels of Lipocalin-2 on patients with primary rhegmatogenous retinal detachment.
Batsos G; Christodoulou E; Vartholomatos G; Galanis P; Stefaniotou M
PLoS One; 2019; 14(12):e0227266. PubMed ID: 31891637
[TBL] [Abstract][Full Text] [Related]
34. Surface Area of Detachment, Proliferative Vitreoretinopathy, and Pulse Pressure, but not AGEs, are Associated With Retinal Redetachment.
Fokkens BT; Mulder DJ; Nugteren MB; Schalkwijk CG; Scheijen JL; Smit AJ; Los LI
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6633-6638. PubMed ID: 27926755
[TBL] [Abstract][Full Text] [Related]
35. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy.
Limb GA; Chignell AH; Cole CJ; Green WT; Webster L; Hollifield RD; Dumonde DC
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001
[TBL] [Abstract][Full Text] [Related]
36. Levels of some cytokines in subretinal fluid in proliferative vitreoretinopathy and rhegmatogenous retinal detachment.
Kenarova B; Voinov L; Apostolov C; Vladimirova R; Misheva A
Eur J Ophthalmol; 1997; 7(1):64-7. PubMed ID: 9101198
[TBL] [Abstract][Full Text] [Related]
37. Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF).
Nicoletti VG; Nicoletti R; Ferrara N; Meli G; Reibaldi M; Reibaldi A
Exp Clin Endocrinol Diabetes; 2003 Jun; 111(4):209-14. PubMed ID: 12845559
[TBL] [Abstract][Full Text] [Related]
38. Correlation of transforming growth factor β-1 vitreous levels with clinical severity of proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment.
Palomares-Ordóñez JL; Sánchez-Ramos JA; Ramírez-Estudillo JA; Robles-Contreras A
Arch Soc Esp Oftalmol (Engl Ed); 2019 Jan; 94(1):12-17. PubMed ID: 30309666
[TBL] [Abstract][Full Text] [Related]
39. Triamcinolone acetonide facilitates removal of the epiretinal membrane and separation of the residual vitreous cortex in highly myopic eyes with retinal detachment due to a macular hole.
Yamamoto N; Ozaki N; Murakami K
Ophthalmologica; 2004; 218(4):248-56. PubMed ID: 15258413
[TBL] [Abstract][Full Text] [Related]
40. Position of macula lutea and presence of proliferative vitreoretinopathy affect vitreous cytokine expression in rhegmatogenous retinal detachment.
Balogh A; Milibák T; Szabó V; Nagy ZZ; Resch MD
PLoS One; 2020; 15(6):e0234525. PubMed ID: 32542038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
